清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease

作者
Pierre‐Yves Crémieux,Marc Van Audenrode,Patrick Lefèbvre
出处
期刊:Current Medical Research and Opinion [Taylor & Francis]
卷期号:22 (12): 2329-2336 被引量:24
标识
DOI:10.1185/030079906x154024
摘要

OBJECTIVE: The purpose of this study was to review and analyze current research to evaluate the dose ratio of epoetin alfa and darbepoetin alfa for the treatment of anemia in chronic kidney disease (CKD) and to identify determinants of the variation in epoetin alfa:darbepoetin alfa dose ratios across studies. METHODS: A systematic review of the literature for comparative switch and non-switch studies of epoetin alfa and darbepoetin alfa treatments in CKD for the period 2000-2005 was performed. Two reviewers independently assessed the quality of the information. Data on the study design and outcomes were collected for each selected study. The dose ratio from epoetin alfa to darbepoetin alfa was calculated for each study, and the results were reported stratified by study characteristics. To control for differences in study design and characteristics that could explain the variability in the relative dosages of the two agents across studies, multivariate regression analysis was conducted. Based on these results, a dose conversion ratio for Canada was estimated. RESULTS: A total of 21 studies involving 16 378 patients exposed to epoetin alfa or darbepoetin alfa in CKD were identified. Univariate analysis of the dose ratios indicated a mean dose ratio of 217:1 (IU of epoetin alfa:mug of darbepoetin alfa). Results from the multivariate analysis demonstrated that the study design (i.e., switch study versus straight comparison studies) and geographical coverage (i.e., United States) affected the results. Based on the multivariate analysis, the dose conversion ratio between epoetin alfa and darbepoetin alfa for Canada was 169:1. CONCLUSIONS: Despite limitations associated with switching studies and the limited total number of studies available, this systematic review based on aggregated results provides further evidence to the clinical community that the dose conversion ratio for epoetin alfa:darbepoetin alfa in CKD patients in Canada is approximately 169:1. At that ratio, treatment with epoetin alfa is 11-18% cheaper than treatment with darbepoetin alfa in Canada.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Qinzhiyuan1990完成签到 ,获得积分10
1秒前
兴奋巧凡完成签到,获得积分10
3秒前
阿浮完成签到 ,获得积分10
4秒前
南风完成签到 ,获得积分10
11秒前
月亮的喵完成签到 ,获得积分20
18秒前
19秒前
俊逸代男发布了新的文献求助10
23秒前
鲜艳的雪曼完成签到,获得积分10
28秒前
A12345678完成签到,获得积分10
28秒前
Edward完成签到,获得积分10
30秒前
张秀伟完成签到,获得积分10
30秒前
lzm完成签到 ,获得积分10
32秒前
LIQIANG完成签到 ,获得积分10
40秒前
Murphy完成签到 ,获得积分10
41秒前
iman完成签到,获得积分10
1分钟前
狂野不乐完成签到,获得积分10
1分钟前
Aboo完成签到,获得积分10
1分钟前
温一完成签到 ,获得积分10
1分钟前
besatified的应助被lovelife采纳,获得10
1分钟前
liu95完成签到 ,获得积分0
1分钟前
从容的水壶完成签到 ,获得积分10
1分钟前
痴情的又亦完成签到,获得积分10
1分钟前
苗苗会喵喵完成签到,获得积分10
1分钟前
冷傲的妙竹完成签到,获得积分10
1分钟前
AmyHu完成签到,获得积分10
1分钟前
小狮子完成签到 ,获得积分10
1分钟前
Ray完成签到 ,获得积分10
1分钟前
白白不喽完成签到 ,获得积分10
2分钟前
Anoxra完成签到 ,获得积分10
2分钟前
独特问梅完成签到,获得积分10
2分钟前
李煜琛完成签到 ,获得积分10
2分钟前
沈惠映完成签到 ,获得积分0
2分钟前
欢呼的访文完成签到,获得积分10
2分钟前
n01W97的应助被科研通管家采纳,获得20
2分钟前
sunflower完成签到,获得积分0
2分钟前
seeyou14完成签到,获得积分0
2分钟前
宝贝的鱼完成签到 ,获得积分10
2分钟前
魔幻友菱完成签到 ,获得积分10
2分钟前
timeless完成签到 ,获得积分10
2分钟前
孤独怀寒完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185483
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783085
什么是DOI,文献DOI怎么找? 3434576
关于科研通互助平台的介绍 2558929
邀请新用户注册赠送积分活动 2481346